NO_LONGER_AVAILABLENCT02174679
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Studying Medullary thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jonsson Comprehensive Cancer Center
- Principal Investigator
- Johannes Czernin, MDUniversity of California, Los Angeles
- Intervention
- 68Ga DOTATATE(drug)
- Eligibility
- 18 years · All sexes
Study locations (1)
- UCLA Hospital, Los Angeles, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02174679 on ClinicalTrials.govOther trials for Medullary thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07566156Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )Astellas Pharma Global Development, Inc.
- RECRUITINGPHASE3NCT07383246CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNCT07142005Cultural Adaptation of an Educational Tool in Medullary Thyroid CancerM.D. Anderson Cancer Center
- RECRUITINGNANCT07138716Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTCLuo Yaping
- ENROLLING BY INVITATIONNCT06852144PET-TC in Thyroid EvaluationIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNANCT06141369Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)Shanghai Jiao Tong University School of Medicine
- RECRUITINGNANCT0627718068Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE1NCT06520319Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaFirst Affiliated Hospital of Fujian Medical University